Kathleen Kahler Fonda

Array ( [id] => 20578484 [patent_doc_number] => 12570726 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-10 [patent_title] => Anti-HIV antibody and method for producing same [patent_app_type] => utility [patent_app_number] => 17/290054 [patent_app_country] => US [patent_app_date] => 2019-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 8 [patent_no_of_words] => 5472 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17290054 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20492653 [patent_doc_number] => 12534516 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-27 [patent_title] => Anti-HIV antibodies [patent_app_type] => utility [patent_app_number] => 17/287188 [patent_app_country] => US [patent_app_date] => 2019-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 41 [patent_figures_cnt] => 13 [patent_no_of_words] => 63696 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 172 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17287188 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18451934 [patent_doc_number] => 20230193213 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => RECOMBINANT ONCOLYTIC NEWCASTLE DISEASE VIRUSES WITH INCREASED ACTIVITY [patent_app_type] => utility [patent_app_number] => 17/419792 [patent_app_country] => US [patent_app_date] => 2019-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16083 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 258 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17419792 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17299935 [patent_doc_number] => 20210395774 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => NOVEL VIRUS VECTOR AND METHODS FOR PRODUCING AND USING SAME [patent_app_type] => utility [patent_app_number] => 17/279330 [patent_app_country] => US [patent_app_date] => 2019-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18089 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17279330 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17480679 [patent_doc_number] => 20220088183 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-24 [patent_title] => CHIMERIC ONCOLYTIC HERPESVIRUS THAT STIMULATES AN ANTITUMOR IMMUNE RESPONSE [patent_app_type] => utility [patent_app_number] => 17/271403 [patent_app_country] => US [patent_app_date] => 2019-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19720 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17271403 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19701730 [patent_doc_number] => 12195745 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-14 [patent_title] => Compositions and methods for modulating transduction efficiency of adeno-associated viruses [patent_app_type] => utility [patent_app_number] => 17/269955 [patent_app_country] => US [patent_app_date] => 2019-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 28 [patent_no_of_words] => 12418 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17269955 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17688250 [patent_doc_number] => 20220195542 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => USE OF PRIMER PROBE COMBINATION AND KIT THEREOF IN HBV DETECTION [patent_app_type] => utility [patent_app_number] => 17/599578 [patent_app_country] => US [patent_app_date] => 2019-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6569 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17599578 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17300922 [patent_doc_number] => 20210396761 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => METHODS FOR SCREENING AND IDENTIFYING AGENTS THAT INHIBIT OR MODULATE THE NUCLEAR EGRESS COMPLEX OF HERPESVIRUSES [patent_app_type] => utility [patent_app_number] => 17/261501 [patent_app_country] => US [patent_app_date] => 2019-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25896 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17261501 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16977960 [patent_doc_number] => 20210222197 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-22 [patent_title] => VIRUS VECTOR PRODUCTION [patent_app_type] => utility [patent_app_number] => 17/055151 [patent_app_country] => US [patent_app_date] => 2019-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13764 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17055151 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19345467 [patent_doc_number] => 20240254430 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-01 [patent_title] => SCALABLE CLARIFICATION PROCESS FOR RECOMBINANT AAV PRODUCTION [patent_app_type] => utility [patent_app_number] => 17/050608 [patent_app_country] => US [patent_app_date] => 2019-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18140 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17050608 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16581466 [patent_doc_number] => 20210015868 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-21 [patent_title] => METHODS OF MANUFACTURING GENETICALLY-MODIFIED LYMPHOCYTES [patent_app_type] => utility [patent_app_number] => 17/042043 [patent_app_country] => US [patent_app_date] => 2019-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31929 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17042043 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16437418 [patent_doc_number] => 20200354744 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-12 [patent_title] => MODIFIED RAAV CAPSID PROTEIN FOR GENE THERAPY [patent_app_type] => utility [patent_app_number] => 16/962748 [patent_app_country] => US [patent_app_date] => 2019-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19077 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16962748 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19777451 [patent_doc_number] => 12226472 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-18 [patent_title] => Foot-and-mouth disease virus-like particle antigen, and vaccine composition, preparation method, and application thereof [patent_app_type] => utility [patent_app_number] => 17/421541 [patent_app_country] => US [patent_app_date] => 2019-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7945 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 303 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17421541 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19318334 [patent_doc_number] => 20240239877 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-18 [patent_title] => ANTIGEN BINDING POLYPEPTIDES [patent_app_type] => utility [patent_app_number] => 16/954988 [patent_app_country] => US [patent_app_date] => 2018-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29895 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16954988 [rel_patent_id] =>[rel_patent_doc_number] =>)